Literature DB >> 21440669

Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

Zobair M Younossi1, Maria Stepanova, Mariam Afendy, Yun Fang, Youssef Younossi, Hesham Mir, Manirath Srishord.   

Abstract

BACKGROUND & AIMS: Chronic liver diseases (CLDs) are major causes of morbidity and mortality worldwide. We assessed changes in the prevalence of different types of CLD in the United States.
METHODS: National Health and Nutrition Examination Surveys conducted between 1988 and 2008 were used to estimate changes in the prevalence and predictors of CLDs. Serologic and clinical data were used to establish the diagnoses of CLDs in 39,500 adults. Statistical analyses were conducted with SUDAAN 10.0 (SAS Institute, Inc, Cary, NC).
RESULTS: The prevalence rates for CLD were 11.78% (1988-1994), 15.66% (1999-2004), and 14.78% (2005-2008). During the same period, the prevalence of hepatitis B virus infection (0.36%, 0.33%, and 0.34%), hepatitis C virus (1.95%, 1.97%, and 1.68%), and alcoholic liver disease (1.38%, 2.21%, and 2.05%) remained generally stable. In contrast, the prevalence of nonalcoholic fatty liver disease (NAFLD) increased from 5.51% to 9.84% to 11.01%. From 1988 to 1994, NAFLD accounted for 46.8% of CLD cases; from 1994 to 2004 its prevalence increased to 62.84%, and then to 75.1% from 2005 to 2008. During these time periods, steady increases were observed in obesity (21.74%, 30.02%, and 33.22%), visceral obesity (35.18%, 48.16%, and 51.43%), type II diabetes (5.55%, 7.88%, and 9.11%), insulin resistance (23.29%, 32.50%, and 35.00%), and hypertension (22.68%, 33.11%, and 34.08%). A multivariate analysis showed that during all time periods, obesity was an independent predictor of NAFLD.
CONCLUSIONS: National Health and Nutrition Examination Surveys data collected from 1988 to 2008 show that the prevalence of major causes of CLD remained stable, except for NAFLD, which increased steadily, along with the prevalence of metabolic conditions. Given the increasing rates of obesity, NAFLD prevalence is expected to contribute substantially to the burden of CLD in the United States.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21440669     DOI: 10.1016/j.cgh.2011.03.020

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  372 in total

1.  Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression.

Authors:  Masayuki Nagahashi; Kazuaki Takabe; Runping Liu; Kesong Peng; Xiang Wang; Yun Wang; Nitai C Hait; Xuan Wang; Jeremy C Allegood; Akimitsu Yamada; Tomoyoshi Aoyagi; Jie Liang; William M Pandak; Sarah Spiegel; Phillip B Hylemon; Huiping Zhou
Journal:  Hepatology       Date:  2015-03-09       Impact factor: 17.425

2.  Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement.

Authors:  Anthony E Samir; Manish Dhyani; Abhinav Vij; Atul K Bhan; Elkan F Halpern; Jorge Méndez-Navarro; Kathleen E Corey; Raymond T Chung
Journal:  Radiology       Date:  2014-11-13       Impact factor: 11.105

3.  Smoking and Liver Disease.

Authors:  Stephanie M Rutledge; Amon Asgharpour
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-12

4.  52-year-old man with liver enzyme abnormalities and elevated ferritin level.

Authors:  Eric M Nelsen; Darrell B Newman; Seth Sweetser
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

Review 5.  The Effects of Physical Exercise on Fatty Liver Disease.

Authors:  Dirk J van der Windt; Vikas Sud; Hongji Zhang; Allan Tsung; Hai Huang
Journal:  Gene Expr       Date:  2017-12-06

6.  Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults.

Authors:  Jennifer C Price; Jennifer L Dodge; Yifei Ma; Rebecca Scherzer; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan Noworolski; Phyllis C Tien
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

7.  Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.

Authors:  Srinivasan Dasarathy; Jaividhya Dasarathy; Amer Khiyami; Lisa Yerian; Carol Hawkins; Ruth Sargent; Arthur J McCullough
Journal:  J Clin Gastroenterol       Date:  2015-02       Impact factor: 3.062

Review 8.  Dietary habits and behaviors associated with nonalcoholic fatty liver disease.

Authors:  Kenichiro Yasutake; Motoyuki Kohjima; Kazuhiro Kotoh; Manabu Nakashima; Makoto Nakamuta; Munechika Enjoji
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

9.  Therapeutic effect of rosuvastatin and propylthiouracil on ameliorating high-cholesterol diet-induced fatty liver disease, fibrosis and inflammation in rabbit.

Authors:  Pao-Yuan Lin; Chih-Hung Chen; Christopher Glenn Wallace; Kuan-Hung Chen; Chia-Lo Chang; Hong-Hwa Chen; Pei-Hsun Sung; Kun-Chen Lin; Sheung-Fat Ko; Cheuk-Kwan Sun; Hsueh-Wen Chang; Pei-Lin Shao; Mel S Lee; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

10.  Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice.

Authors:  Justin R Henning; Christopher S Graffeo; Adeel Rehman; Nina C Fallon; Constantinos P Zambirinis; Atsuo Ochi; Rocky Barilla; Mohsin Jamal; Michael Deutsch; Stephanie Greco; Melvin Ego-Osuala; Usama Bin-Saeed; Raghavendra S Rao; Sana Badar; Juan P Quesada; Devrim Acehan; George Miller
Journal:  Hepatology       Date:  2013-06-24       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.